CircVAPA could activate the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway by modulating the miR-377-3p and miR-494-3p/insulin-like growth factor 1 receptor (IGF1R) axis to accelerate small cell lung cancer progression [29]. This evidence concerns the gene AKT1 and small cell lung carcinoma.